Other antidiabetic treatments targeting Wnt signaling pathway are aFGF for use in vascular complications of diabetes [12], glucagon-like peptide-1 (GLP-1) receptor agonists because of their effects on diabetic nephropathy or bone metabolism [14,104], and class α-glucosidase inhibitors and peroxisome proliferator-activated receptors (PPARs) agonists for use in Alzheimer disease (AD) [105]. Here, GCG is linked to early-onset autosomal dominant Alzheimer disease.